Truvestments Capital LLC Purchases 1,669 Shares of Omeros Co. (NASDAQ:OMER)

Truvestments Capital LLC grew its position in shares of Omeros Co. (NASDAQ:OMER) by 116.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,102 shares of the biopharmaceutical company’s stock after acquiring an additional 1,669 shares during the period. Truvestments Capital LLC’s holdings in Omeros were worth $31,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of OMER. Charles Schwab Investment Management Inc. raised its position in Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after purchasing an additional 18,454 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares during the period. HighTower Advisors LLC raised its holdings in shares of Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 4,000 shares in the last quarter. State Street Corp lifted its stake in Omeros by 0.3% in the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 3,839 shares during the period. Finally, Wellington Management Group LLP bought a new stake in Omeros in the third quarter valued at $305,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on OMER shares. D. Boral Capital restated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Thursday, February 20th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Omeros currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

Shares of NASDAQ OMER opened at $7.86 on Friday. The company has a 50 day simple moving average of $8.86 and a two-hundred day simple moving average of $7.12. Omeros Co. has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The company has a market capitalization of $455.49 million, a price-to-earnings ratio of -3.40 and a beta of 2.03.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.